PRO DEX INC generated $77.548 million in fiscal 2026 net sales, compared with $66.593 million in fiscal 2025, while medical device products and related services supplied 98% of revenue. Customer concentration is significant for investors because the top three customers represented 92% of fiscal 2026 sales.
Key Highlights
- PRO DEX INC’s three largest customers represented 92% of fiscal 2026 sales, with its biggest customer accounting for 78%.
- Research and development expenses amounted to $3.3 million in fiscal 2026, down from $3.6 million in fiscal 2025.
- The company identifies competition, Cybersecurity threats and Patent infringement claims among its business risks.
Medical device products and related services accounted for 98% of revenue. Non-recurring engineering Revenue represented 2% of fiscal 2026 revenue, compared with 1% in fiscal 2025.
Fiscal Sales And Margins
Cost of sales totaled $53.213 million in fiscal 2026, equal to 69% of net sales, compared with $47.083 million, or 71%, in fiscal 2025. Gross Profit reached $24.335 million, or 31% of net sales, versus $19.510 million, or 29%, in the earlier fiscal year. General and administrative expenses were $7.483 million, representing 10% of net sales, compared with $4.841 million, or 7%, in fiscal 2025. Research and Development costs were $3.345 million, equal to 4% of net sales, versus $3.636 million, or 6%, previously. Selling expenses amounted to $516 thousand in fiscal 2026 and $344 thousand in fiscal 2025. Total operating expenses were $11.344 million, or 14% of net sales, compared with $8.821 million, or 13%, in fiscal 2025.
Engineering Costs And Services
PRO DEX recorded $3.3 million of research and development expenses in fiscal 2026, compared with $3.6 million in fiscal 2025. The amounts exclude approximately $82,000 and $73,000, respectively, in labor and related expenses reimbursed by customers through non-recurring engineering billings. The services can involve development work performed under customer contracts, including the evaluation, design or customization of medical devices.
Customer Concentration Risks
The top three customers accounted for 92% of fiscal 2026 sales, while the largest customer represented 78%. A Supply agreement covers purchases of surgical handpieces through calendar 2028, and purchase orders have been placed for deliveries in 2027. PRO DEX states that losing the largest customer, or experiencing a material reduction in purchases from that customer or other significant customers, would severely affect its business, financial condition, cash flows, revenue and operating results. The company also identifies dependence on its core business area as a risk.
Competition And Cybersecurity
Competition involving products and services developed by PRO DEX, its customers’ internal development and Manufacturing departments, or competitors could cause price or market-share erosion. The company also says its products and services may not achieve broad market acceptance or successfully compete with offerings aimed at the same customers. Cybersecurity threats are described as numerous and evolving risks that could adversely affect the business. Patent infringement assertions or defenses could materially and adversely affect operations because of the costs involved.




Please wait processing your request...